Aa
Add -on of peg interferon to a stable nucleoside, hbsag loss 40%
Add -on of peg interferon to a stable nucleoside regimen led to loss of HBs Ag in chronic hepatitis HBe Ag negative patients
D. Ouzan1; G. Penaranda2; H. Joly1; H. Khiri2; P. Halfon2
1. Institut Arnault Tzanck, Saint-Laurent du Var, France.
2. Laboratoire ALPHABIO, Marseille, France.
Objectives: Suppression of HBV viral load by nucleoside treatment reduces disease progression but requires indefinite treatment. Hbs Ag loss is a rare event after long term treatment with analogues therapy. In HBe Ag negative patients peg interferon alpha 2a for 96 weeks improved the sustained responses rate versus 48 weeks. It is of interest to know whether the addition of peg interferon for 96 weeks to a stable nucleoside therapy will reduce quantitative HBs-Ag which may follow by HBs Ag loss.
Methods: We analyzed HBs Ag levels of 10 patients who received additional peg
D. Ouzan1; G. Penaranda2; H. Joly1; H. Khiri2; P. Halfon2
1. Institut Arnault Tzanck, Saint-Laurent du Var, France.
2. Laboratoire ALPHABIO, Marseille, France.
Objectives: Suppression of HBV viral load by nucleoside treatment reduces disease progression but requires indefinite treatment. Hbs Ag loss is a rare event after long term treatment with analogues therapy. In HBe Ag negative patients peg interferon alpha 2a for 96 weeks improved the sustained responses rate versus 48 weeks. It is of interest to know whether the addition of peg interferon for 96 weeks to a stable nucleoside therapy will reduce quantitative HBs-Ag which may follow by HBs Ag loss.
Methods: We analyzed HBs Ag levels of 10 patients who received additional peg
Funny, same paper, but different numbers!
J Clin Virol. 2012 Feb 23. [Epub ahead of print]
Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B.
Kittner JM, Sprinzl MF, Grambihler A, Weinmann A, Schattenberg JM, Galle PR, Schuchmann M.
Source
I. Medical Department, University Hospital Mainz, Langenbeckstr. 1, 55131 Mainz, Germany.
Abstract
BACKGROUND:
Nucleos(t)ides effectively halt disease progression in hepatitis B but require long-term medication.
OBJECTIVES:
To determine whether add-on of peg-IFN to an ongoing nucleos(t)ide therapy accelerates decline of HBsAg and induces seroconversion.
STUDY DESIGN:
We observed HBsAg kinetics in 12 patients on a stable oral therapy with undetectable HBV-DNA who additionally received peg-IFN-alfa 2a as an individualized therapy. 3 patients were HBeAg positive. Mean baseline HBsAg was 4695 (range 16-15,120)IU/ml.
RESULTS:
A continuous decline of HBsAg was observed in 2 patients. The slope, respectively, became detectable at week 8 or 16. HBsAg had dropped by 2.90log(10) or 4.25log(10) fold at week 48, and anti-HBs appeared at week 40 or 32. Patient A - HBe-positive, genotype A, F3 fibrosis - had been HBV-DNA negative for 10 months receiving entecavir plus tenofovir. Previous therapy with peg-IFN had been unsuccessful, but now the patient experienced HBeAg seroconversion at week 24. Patient B - HBeAg negative, genotype D, cirrhosis - had a low initial HBsAg level of 16U/l. Receiving entecavir, his HBV-DNA had previously been non-detectable for 27 months. In the remaining 10 patients HBsAg declined only by a mean of 0.09log(10) (range 0.01-0.25log(10)) after 8-24 (mean 16.4) weeks, and therefore, peg-IFN was stopped. No unexpected side effects were observed.
DISCUSSION:
We observed that the add-on of peg-IFN induced HBsAg seroconversion in 2 out of 12 patients. Response rates may have been higher with prolongation of therapy. The add-on concept merits to be evaluated in a clinical trial.
J Clin Virol. 2012 Feb 23. [Epub ahead of print]
Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B.
Kittner JM, Sprinzl MF, Grambihler A, Weinmann A, Schattenberg JM, Galle PR, Schuchmann M.
Source
I. Medical Department, University Hospital Mainz, Langenbeckstr. 1, 55131 Mainz, Germany.
Abstract
BACKGROUND:
Nucleos(t)ides effectively halt disease progression in hepatitis B but require long-term medication.
OBJECTIVES:
To determine whether add-on of peg-IFN to an ongoing nucleos(t)ide therapy accelerates decline of HBsAg and induces seroconversion.
STUDY DESIGN:
We observed HBsAg kinetics in 12 patients on a stable oral therapy with undetectable HBV-DNA who additionally received peg-IFN-alfa 2a as an individualized therapy. 3 patients were HBeAg positive. Mean baseline HBsAg was 4695 (range 16-15,120)IU/ml.
RESULTS:
A continuous decline of HBsAg was observed in 2 patients. The slope, respectively, became detectable at week 8 or 16. HBsAg had dropped by 2.90log(10) or 4.25log(10) fold at week 48, and anti-HBs appeared at week 40 or 32. Patient A - HBe-positive, genotype A, F3 fibrosis - had been HBV-DNA negative for 10 months receiving entecavir plus tenofovir. Previous therapy with peg-IFN had been unsuccessful, but now the patient experienced HBeAg seroconversion at week 24. Patient B - HBeAg negative, genotype D, cirrhosis - had a low initial HBsAg level of 16U/l. Receiving entecavir, his HBV-DNA had previously been non-detectable for 27 months. In the remaining 10 patients HBsAg declined only by a mean of 0.09log(10) (range 0.01-0.25log(10)) after 8-24 (mean 16.4) weeks, and therefore, peg-IFN was stopped. No unexpected side effects were observed.
DISCUSSION:
We observed that the add-on of peg-IFN induced HBsAg seroconversion in 2 out of 12 patients. Response rates may have been higher with prolongation of therapy. The add-on concept merits to be evaluated in a clinical trial.
HBsAg by -2,6log10 and -3,66 log10 was observed at week 32 and 36, respectively. = HBsAg by -457 and -4570 was observed at week 32 and 36, respectively.
3.66 log = 10 cube 3.66 (actualy cube is 3 , but i don't know the English term ) = 4570 ~4600
"so 3.66logs should be between 5000 to 9999, may be about 7000iu/ml, i dont now if there is a way to make a precise number from 3.66log, i guess so, anybody expert with maths"
I'm not an math expert but as far as I understand 3.66log = 4 600 UI (log(4600) = 3.66)
I'm not an math expert but as far as I understand 3.66log = 4 600 UI (log(4600) = 3.66)
i am talking about the german trial with only 2 responding patients which says:
Results: During add-on therapy, in 2 patients a continuous decline of quantitative HBsAg by -2,6log10 and -3,66 log10 was observed at week 32 and 36, respectively.
they just say the hbsag quantity baseline on the guy with low hbsag on etv, about 16iu/ml which should be closer to 2logs so i think the 3.66log is about the only other patient on tdf+etv
i have to say many researchers are so bad at reporting, it is so easy to be precise on the numbers, on the contrary some of them are so confusing on the most important tests
another thing i do hate is the old way to report alt levels as ULN when they dont even say what they consider as normal alt
Results: During add-on therapy, in 2 patients a continuous decline of quantitative HBsAg by -2,6log10 and -3,66 log10 was observed at week 32 and 36, respectively.
they just say the hbsag quantity baseline on the guy with low hbsag on etv, about 16iu/ml which should be closer to 2logs so i think the 3.66log is about the only other patient on tdf+etv
i have to say many researchers are so bad at reporting, it is so easy to be precise on the numbers, on the contrary some of them are so confusing on the most important tests
another thing i do hate is the old way to report alt levels as ULN when they dont even say what they consider as normal alt
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
